JNK-IN-8  (Synonyms: JNK Inhibitor XVI)

JNK-IN-8 (JNK Inhibitor XVI) (GMP) is JNK-IN-8 (HY-13319) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. JNK-IN-8 is a potent JNK inhibitor with IC₅₀s of 4.7 nM, 18.7 nM, and 1 nM for JNK1, JNK2, and JNK3, respectively^[1].

IC50: 4.7/18.7/1 nM (JNK1/2/3)^[1]

JNK-IN-8 (GMP) (10 μM) reduces WNT3A-mediated neuronal differentiation^[1].
JNK-IN-8 (GMP) (2 μM, 7 days) enhances the self-renewal of human hematopoietic stem cells (HSCs) through the downregulation of C-JUN phosphorylation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

507.59

C₂₉H₂₉N₇O₂

1410880-22-6

CC1=CC(NC(C2=CC=CC(NC(/C=C/CN(C)C)=O)=C2)=O)=CC=C1NC3=NC=CC(C4=CN=CC=C4)=N3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Bengoa-Vergniory N, et al. A switch from canonical to noncanonical Wnt signaling mediates early differentiation of human neural stem cells. Stem Cells. 2014 Dec;32(12):3196-208.  [Content Brief]

  [2]. Xiao X, et al. Targeting JNK pathway promotes human hematopoietic stem cell expansion. Cell Discov. 2019 Jan 8;5:2.  [Content Brief]